CBDWire Editorial Coverage: Mounting research from around the world suggests marijuana’s potential to treat multiple medical conditions ranging from chronic pain to cancer, epilepsy, HIV/AIDS, anxiety and more. Predicted to reach $55.8 billion by 2025(1), the global medical marijuana industry presents to investors a wide array of investment opportunities, driven by increasing demand for therapeutic applications of the drug. In turn, funds raised through the public market give marijuana companies the chance to raise capital to build stronger portfolios, increase their market reach and revenue, and offer cannabis-based alternatives to traditional medicine. Companies such as ChineseInvestors.com, Inc. (CIIX) (Profile: CIIX), Medical Marijuana, Inc. (MJNA), CV Sciences, Inc. (CVSI), Terra Tech Corp. (TRTC), and Marijuana Company of America, Inc. (MCOA) are operating in the medical marijuana scene and are steadily building a strong reputation as leading providers of cannabis-based health and wellness products and services.
Created as a premier source of financial information for Chinese-speaking investors, ChineseInvestors.com (CIIX) is carving for itself a hefty portion of the cannabis market through diversified entry points. Adding to its current operations, CIIX earlier this week announced (http://nnw.fm/3nlZM) its entry into China’s skincare industry though the impending launch of a new line of cannabidiol-based skincare products.
“Although ancient Chinese recognized the medicinal properties of the cannabis plant, CBD extract appears to be largely unrecognized in China today for its benefits, including but not limited to, its potential benefits to the largest visible human organ, the skin. The effects of increased air pollution on the human body are a growing concern for many in China. With regard to our skin, toxins in air pollution promote the production of free radicals, causing premature aging including coarse wrinkles and dark spots. However, some dermatologists believe that the anti-oxidants and anti-inflammatory agents in CBD can potentially have anti-aging effects on the skin,” the company stated in the press release.
The opportunity here is significant, as you look at the broader market. China is currently the second largest consumer of skincare products, generating annual retail sales of more than $29.6 billion2. Research from ReportLinker estimates that Chinese skincare product retail sales will reach $36.3 billion this year.
The CBD Magic Hemp Series, to be launched by early September by CIIX’s wholly-owned CBD Biotechnology Co. Ltd. subsidiary (http://nnw.fm/VC7oZ), will position CIIX as a first mover in this previously untapped sector of the Chinese skincare industry. CIIX has filed a record of the product line with the Chinese Food and Drug Administration, and the company anticipates capturing “100% of China’s market share in this novel skin care products category,” since, to its knowledge, other manufacturers have not yet entered the cannabis skincare product market in China.
Again targeting an untapped niche of the marijuana market, CIIX operates the first Chinese-language online store selling cannabidiol (CBD) products. In December 2016, CIIX launched www.ChineseCBDoil.com in Shanghai, catering to a growing audience of Chinese people interested in the benefits of CBD-based products for the treatment of various medical conditions such as stress, anxiety, Alzheimer’s disease, and others. In conjunction with the launch of the website, CIIX introduced the first Yelp-style social media app in Chinese. The app, approved by the Apple store, is a platform for reviews and discussions about cannabis products and provides a comprehensive database of dispensaries and marijuana strains, all in the Chinese language.
CIIX is also getting ready to open its first retail store, primarily targeting the Chinese community in San Gabriel, California. The store will sell the company’s new OptHemp product line, launched by subsidiary ChineseHempOil.com, Inc., to treat pain and inflammation. In July, CIIX announced (http://nnw.fm/6ThNn) that www.ChineseHempOil.com will accept bitcoin payments for its health products, food and beverages.
Another recognizable marijuana company focused on market firsts is Medical Marijuana, Inc. (MJNA). MJNA was the first publicly-traded marijuana company in the United States; the first to make cannabidiol available domestically and abroad; and the first to establish a global CBD pipeline that made beneficial cannabinoid products available to people all over the world. In addition to establishing an international CBD pipeline, providing support services to the cannabis industry and working to develop new markets, MJNA is focusing on the development and distribution of CBD hemp oil health products such as HempMeds® and Kannaway®, in addition to developing cannabis medication via subsidiaries AXIM Biotechnologies, Kannalife™ Sciences, and HempMeds®. The companies are looking into different delivery methods for marijuana-based therapies and are targeting a wide range of conditions including Alzheimer’s, Parkinson’s, epilepsy, multiple sclerosis, cancer, chronic pain and more.
Medical marijuana player CV Sciences (CVSI) operates its corner of the market via two different business segments: pharmaceuticals and consumer products. Its pharmaceutical division is developing synthetic CBD-based medicines for various medical conditions, with approval of the U.S. Food and Drug Administration. Its pipeline currently includes a CBD-based product designed to support cessation of tobacco addiction. The consumer products division manufactures and distributes plant-based CBD products designed to enhance quality of life. CVSI’s flagship consumer products, PlusCBD Oil and Purified Liquids vaping blends, are already distributed nationwide via health care providers, health food stores and online.
Terra Tech (TRTC) is a vertically-integrated cannabis agriculture company that owns multiple subsidiaries in the medical marijuana space. One of these subsidiaries is Blüm™, a retail medical cannabis company that provides medical cannabis as an alternative treatment for patients with chronic conditions. Also offering cannabis to the adult-use market in Nevada, where the sale of marijuana for recreational purposes is legal, Blüm offers recreational and medicinal consumer products such as flowers and concentrates produced according to the highest standards of potency and purity. Terra Tech is committed to cultivating only high-quality medical marijuana and providing it to qualified and registered medical marijuana establishments throughout the United States. At the same time, the company is continuing research to cultivate and cross-breed medical marijuana strains for the treatment of many different medical conditions.
As demand for medical marijuana grows, so too does the need for grow space. Marijuana Company of America (MCOA) is primarily focused on the marketing and distribution of hemp via a diverse portfolio of companies, brands, joint ventures and investments such as hempSMART, Club Harmoneous, GateC Research, Bougainville and MoneyTrac Technology. The company earlier this month said it has received financing that it will use to develop a state-of-the-art 30,000-square-foot greenhouse grow facility in Oroville, Washington, with joint-venture partner Bougainville Ventures, Inc. At full capacity, the facility is expected to accommodate cannabis production and processing of its tenant, a Tier 3, I-502 licensed grower. MCOA said it plans to replicate this business model to build its real estate portfolio and increase revenues.
These public companies, expanding their market reach and brand recognition in their respective niches of the medical marijuana market, provide ample opportunities for investors looking for an entrance into the booming medical marijuana market. Proponents of marijuana for medical purposes point to a growing number of studies that confirm the health benefits of cannabis, setting the industry on track to continue its strong performance and become a key industry and engine of economic growth.
For more information on ChineseInvestors.com, please visit: ChineseInvestors.com (CIIX)
CBDWire (CBDW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
DISCLAIMER: CBDWire (CBDW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CBDW are solely those of CBDW. Readers of this Article and content agree that they cannot and will not seek to hold liable CBDW for any investment decisions by their readers or subscribers. CBDW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CBDW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
CBDW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CBDW undertake no obligation to update such statements.